Megan Manuel

437 total citations
27 papers, 323 citations indexed

About

Megan Manuel is a scholar working on Hematology, Molecular Biology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Megan Manuel has authored 27 papers receiving a total of 323 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Hematology, 15 papers in Molecular Biology and 7 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Megan Manuel's work include Acute Myeloid Leukemia Research (17 papers), Histone Deacetylase Inhibitors Research (9 papers) and Cancer, Hypoxia, and Metabolism (7 papers). Megan Manuel is often cited by papers focused on Acute Myeloid Leukemia Research (17 papers), Histone Deacetylase Inhibitors Research (9 papers) and Cancer, Hypoxia, and Metabolism (7 papers). Megan Manuel collaborates with scholars based in United States, Israel and United Kingdom. Megan Manuel's co-authors include Susan Lyerly, Bayard L. Powell, Leslie R. Ellis, Timothy S. Pardee, Sarah Dralle, Scott Isom, Lance D. Miller, David D. Hurd, Dmitriy Berenzon and Dianna S. Howard and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Megan Manuel

25 papers receiving 320 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Megan Manuel United States 7 205 145 132 42 37 27 323
Susan Lyerly United States 7 205 1.0× 145 1.0× 136 1.0× 47 1.1× 38 1.0× 26 320
Sarah Dralle United States 6 205 1.0× 143 1.0× 129 1.0× 41 1.0× 34 0.9× 23 308
Monica Franzoni Italy 9 181 0.9× 39 0.3× 71 0.5× 31 0.7× 22 0.6× 10 261
Deanna P. Porras Canada 8 181 0.9× 60 0.4× 199 1.5× 61 1.5× 16 0.4× 13 389
Xiaoxin Hao China 8 151 0.7× 63 0.4× 74 0.6× 57 1.4× 16 0.4× 16 266
Ligen Liu China 11 168 0.8× 64 0.4× 142 1.1× 89 2.1× 20 0.5× 29 372
Roberta Spinelli Italy 11 203 1.0× 110 0.8× 38 0.3× 23 0.5× 32 0.9× 16 301
Salih Demir Germany 9 120 0.6× 35 0.2× 40 0.3× 52 1.2× 47 1.3× 14 217
Catherine E. Jenkins Canada 6 140 0.7× 59 0.4× 51 0.4× 51 1.2× 51 1.4× 8 222
Marena R. Niewisch Germany 7 125 0.6× 40 0.3× 84 0.6× 16 0.4× 21 0.6× 16 324

Countries citing papers authored by Megan Manuel

Since Specialization
Citations

This map shows the geographic impact of Megan Manuel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Megan Manuel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Megan Manuel more than expected).

Fields of papers citing papers by Megan Manuel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Megan Manuel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Megan Manuel. The network helps show where Megan Manuel may publish in the future.

Co-authorship network of co-authors of Megan Manuel

This figure shows the co-authorship network connecting the top 25 collaborators of Megan Manuel. A scholar is included among the top collaborators of Megan Manuel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Megan Manuel. Megan Manuel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Reed, Daniel, Scott Isom, Leslie R. Ellis, et al.. (2023). Real-world outcomes of adult patients with acute lymphoblastic leukemia treated with a modified CALGB 10102 regimen. Annals of Hematology. 102(4). 897–906.
2.
Szabo, Shelagh M., et al.. (2023). The changing epidemiology of preterm labour and delivery: A systematic literature review. SHILAP Revista de lepidopterología. 3(1). 1 indexed citations
3.
Anderson, Rebecca G., Lance D. Miller, Scott Isom, et al.. (2022). Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia. Nature Communications. 13(1). 1673–1673. 28 indexed citations
4.
Manuel, Megan, et al.. (2022). BRIVEST: A ‘real-world’ observational, single-centre study investigating the efficacy, safety and tolerability of Brivaracetam. Epilepsy & Behavior. 138. 108985–108985. 9 indexed citations
5.
Woods, R., Leslie R. Ellis, Rupali Bhave, et al.. (2021). A Pilot Phase II Study of the Feasibility and Efficacy of Vincristine Sulfate Liposome Injection in Patients With Relapsed or Refractory Acute Myeloid Leukemia. Journal of Hematology. 10(1). 1–7. 2 indexed citations
6.
Mehta, Vivek, Scott Isom, Leslie R. Ellis, et al.. (2021). Efficacy of 10-day decitabine in acute myeloid leukemia. Leukemia Research. 103. 106524–106524. 5 indexed citations
7.
Dralle, Sarah, Megan Manuel, Susan Lyerly, et al.. (2021). Incidence of Breakthrough Fungal Infections in Acute Myeloid Leukemia Patients Receiving Low Intensity Therapy in the Upfront and Relapsed/Refractory Setting. Blood. 138(Supplement 1). 3372–3372. 3 indexed citations
8.
Pardee, Timothy S., Susan Lyerly, Sarah Dralle, et al.. (2020). Frontline Selinexor and Chemotherapy Is Highly Active in Older Adults with Acute Myeloid Leukemia (AML). Blood. 136(Supplement 1). 24–25. 4 indexed citations
9.
Pardee, Timothy S., Rebecca G. Anderson, Scott Isom, et al.. (2018). A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia. Clinical Cancer Research. 24(9). 2060–2073. 80 indexed citations
10.
11.
Pardee, Timothy S., Scott Isom, Leslie R. Ellis, et al.. (2017). Interim Analysis of a Single Arm Phase II Study of Cpi-613 in Combination with High Dose Cytarabine and Mitoxantrone for Patients with Relapsed or Refractory AML. Blood. 130. 2626–2626. 1 indexed citations
12.
Pardee, Timothy S., Lance D. Miller, Scott Isom, et al.. (2016). TCA Cycle Inhibition By Cpi-613 Increases Sensitivity to Chemotherapy in Older and Poor Risk Acute Myeloid Leukemia (AML). Blood. 128(22). 4062–4062. 4 indexed citations
13.
Ahmed, Tamjeed, Heidi D. Klepin, Scott Isom, et al.. (2015). High dose cytarabine, mitoxantrone and l-asparaginase (HAMA) salvage for relapsed or refractory acute myeloid leukemia (AML) in the elderly. Leukemia Research. 39(9). 945–949. 19 indexed citations
14.
Pardee, Timothy S., King Lee, John Luddy, et al.. (2014). A Phase I Study of the First-in-Class Antimitochondrial Metabolism Agent, CPI-613, in Patients with Advanced Hematologic Malignancies. Clinical Cancer Research. 20(20). 5255–5264. 91 indexed citations
15.
16.
Pardee, Timothy S., Kristin M. Stadelman, Scott Isom, et al.. (2014). A phase I study of the mitochondrial metabolism inhibitor CPI-613 in combination with high-dose ara-C (HDAC) and mitoxantrone for relapsed or refractory acute myeloid leukemia (AML).. Journal of Clinical Oncology. 32(15_suppl). 7028–7028. 1 indexed citations
17.
Tawfik, Bernard, Susan Lyerly, Heidi D. Klepin, et al.. (2013). Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML). Annals of Hematology. 93(1). 47–55. 46 indexed citations
18.
Ahmed, Tamjeed, Timothy S. Pardee, Scott Isom, et al.. (2013). High Dose Cytarabine, Mitoxantrone and L-Asparaginase (HAMA) Salvage For Relapsed Or Refractory Acute Myeloid Leukemia (AML) In The Elderly. Blood. 122(21). 2700–2700. 1 indexed citations
19.
Pardee, Timothy S., Denise Levitan, David D. Hurd, et al.. (2012). Evaluation of the first-in-class antimitochondrial metabolism agent CPI-613 in hematologic malignancies.. Journal of Clinical Oncology. 30(15_suppl). 6524–6524. 2 indexed citations
20.
Powell, Bayard L., Ralph B. D’Agostino, Denise Levitan, et al.. (2008). High Dose Cytarabine and Clofarabine (HiDAC → CLOF) in Relapsed or Refractory Acute Myeloid Leukemia, a Phase 2 Trial.. Blood. 112(11). 1936–1936. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Susan Lyerly Breakdown of academic impact, for papers by Sarah Dralle Breakdown of academic impact, for papers by Monica Franzoni Breakdown of academic impact, for papers by Deanna P. Porras Breakdown of academic impact, for papers by Xiaoxin Hao Breakdown of academic impact, for papers by Ligen Liu Breakdown of academic impact, for papers by Roberta Spinelli Breakdown of academic impact, for papers by Salih Demir Breakdown of academic impact, for papers by Catherine E. Jenkins Breakdown of academic impact, for papers by Marena R. Niewisch
Rankless by CCL
2026